As of December 23, 2024, the average one-year price target for Regeneron Pharmaceuticals is $1,093.96/share. The forecasts range from a low of $570.65 to a high of $1,291.50.

SciFest, Ireland’s largest and most inclusive STEM fair programme for second-level students, has announced its return ahead ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

LateralCare, a leader in innovative healthcare technology solutions, is proud to announce the appointment of Niobis Queiro as its new Chief Product Officer. With over three decades of expertise in ...

Additionally, Regeneron and Sanofi have a second COPD candidate in IL-33 inhibitor itepekimab, which is being tested in two phase 3 trials.

Bespoke Partners, the largest retained executive search and leadership advisory firm for software companies, is pleased to announce that Jay Nguyen has joined the firm as a Partner in the Product & ...

As Finance Director at Oxular, sold to Regeneron in January 2025 ... organisational growth and clinical programs. Her extensive background includes senior finance roles in a number of biotechs ...

Instilling Goodness Developing Virtue School (IGDVS) is a private K-12 school nestled within the serene grounds of the City ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...